US FDA removes partial clinical hold on Idenix HCV candidate
This article was originally published in Scrip
Executive Summary
Idenix Pharmaceuticals has been notified by the US FDA that the partial clinical hold on its hepatitis C virus treatment candidate IDX184 has been lifted and that it can continue with a Phase IIb trial evaluating the product, the company said.